Acute Kidney Injury: From Early Signs to Chronic Risk
- Share via
Five Key Facts
- AKI can be classified as prerenal, intrinsic, or postrenal, with KDIGO criteria guiding diagnosis.
- New biomarkers like NGAL and cystatin C allow earlier and more precise detection of AKI.
- Preventing AKI involves managing high-risk patients and avoiding nephrotoxins.
- The concept of AKD bridges AKI and CKD, emphasizing the need for follow-up care.
- Timely intervention, biomarker-guided strategies, and nephrology referrals can prevent long-term kidney damage.
Acute kidney injury (AKI) isn’t just a short-term problem—it’s the start of a longer kidney health journey. AKI was previously called ‘acute renal failure’ or ‘renal failure’ but the terminology has evolved to reflect the spectrum of kidney injury. AKI occurs when the kidneys suddenly stop filtering waste products from the blood and the kidney function changes rapidly. This complication is very different from diseases such as Polycystic Kidney Disease, which is a genetic disease and genetic disorder caused by gene mutations passed from biological parents to their children.
Whether it happens in the ICU or outpatient clinic AKI carries a big burden: increased risk of hospitalization, long term dialysis and even premature death. AKI is common in hospitalized patients and patients admitted to hospital and impacts outcomes and length of stay.
Recognizing it early, treating it promptly and understanding the link to chronic kidney disease (CKD) is key to preserving kidney function and better patient outcomes. AKI and CKD are both forms of renal disease and show the continuum between acute and chronic conditions.
Let’s look at how AKI is classified, how to detect it early and what modern tools and strategies are helping clinicians change the trajectory from injury to recovery.
Table of Contents
- Classification and Diagnosis of AKI
- Prevention and Risk Factor Mitigation
- Biomarker-Guided Management
- AKI-to-CKD Continuum and Acute Kidney Disease (AKD)
- Clinical Management Principles
- Closing Thoughts
- References
Classification and Diagnosis of AKI
AKI is classified by where the problem starts:
- Prerenal: Caused by decreased blood flow to the kidneys (like dehydration or heart failure). Prerenal AKI is mainly due to reduced blood flow, decreased renal perfusion and changes in renal blood flow. Vascular causes like renal artery stenosis can also contribute.
- Intrinsic renal: Due to direct damage to the kidney tissue (e.g. glomerulonephritis, acute tubular necrosis). Intrinsic renal causes include acute interstitial nephritis, glomerular diseases and cytotoxic etiologies like tumor lysis syndrome. In some cases a kidney biopsy may be needed to identify the specific pathology. Autoimmune disease can also cause glomerulonephritis or vasculitis of the kidneys.
- Postrenal: From obstruction in the urinary tract (like kidney stones or enlarged prostate). Urinary obstruction, bladder outlet obstruction and blockage at the renal pelvis can all cause postrenal AKI. In men prostate cancer is a cause of bladder outlet obstruction. [1]
The KDIGO clinical practice guideline (Kidney Disease: Improving Global Outcomes) defines AKI using changes in serum creatinine levels and urine output. The urine output criteria are also used in AKI staging, such as less than 0.5 mL/kg/h for specified durations.
The Acute Kidney Injury Network (AKIN) is another classification system that incorporates both serum creatinine and urine output criteria. Early detection and classification are key, with identification of renal dysfunction and monitoring of glomerular filtration rate (GFR) as key measures of kidney health.
But while these have been the clinical mainstays, they aren’t always fast or specific enough to catch injury early. Serum creatinine level and blood urea nitrogen are traditional markers for assessing renal function but both have limitations in sensitivity and specificity.
That’s where newer biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and cystatin C come in. These tools are changing early detection, helping clinicians distinguish between mild, reversible cases and more severe or ongoing damage [2] [3].
A 2021 article highlights the importance of fluid balance, electrolyte monitoring and timely renal replacement therapy (RRT) when AKI is confirmed [3]. In the outpatient space, some reviews suggest early medication adjustment and specialist referrals can reduce complications in patients managed outside the hospital [4].
In the context of pathophysiology blood clots can cause vascular obstruction leading to AKI and red blood cells may be seen in kidney biopsies in certain conditions such as anticoagulant-related nephropathy. [5]
Prevention and Risk Factor Mitigation
Mitigation
Prevention starts by identifying who’s most at risk. People with diabetes, hypertension, chronic heart failure, or advanced age are more likely to develop AKI—especially during acute illnesses or when exposed to nephrotoxic medications like NSAIDs or contrast agents. Both patient-related and treatment-related risk factors such as underlying chronic diseases, recent infections, trauma or major surgeries play a key role in increasing the likelihood of AKI.
According to a 2020 Journal of Clinical Medicine review, risk mitigation means taking a proactive, team-based approach: monitor hydration, avoid nephrotoxins and assess kidney function during high-risk scenarios like surgery or infection [7]. It’s especially important to identify high risk patients, such as those undergoing major procedures like cardiac surgery and tailor perioperative management strategies to prevent renal complications.
Hospital-based strategies such as standardized monitoring protocols and early nephrology involvement can also reduce AKI rates as emphasized by the American Journal of Kidney Diseases Core Curriculum [11].
In a more recent 2025 article in Lakartidningen Swedish clinicians advocate for a streamlined system to identify and intervene early in AKI cases, especially in older adults or those with fluctuating blood pressure [10].
Biomarker-Guided Management
Relying solely on serum creatinine to assess kidney health is a bit like using a smoke detector after the fire’s already burning. Biomarkers offer a more sensitive way to detect kidney injury before significant function is lost. Blood tests are essential for detecting changes in kidney function and guiding the management of AKI patients.
A 2022 review in Medicina presents compelling evidence that biomarkers can guide both diagnosis and risk stratification, helping clinicians decide when to intensify care or when to hold off on aggressive treatments [6].
These biomarkers also help distinguish between transient AKI (due to things like dehydration) and persistent AKI, which is more likely to result in long-term damage. This distinction is critical when managing critically ill patients or adjusting medications like ACE inhibitors and diuretics.
AKI-to-CKD Continuum and Acute Kidney Disease (AKD)
One of the biggest changes in kidney medicine over the past decade is that AKI doesn’t always resolve cleanly. Many patients recover creatinine levels but their kidneys never return to full health. This transitional phase, called acute kidney disease (AKD), spans from 7 to 90 days after AKI onset. Renal recovery after AKI depends on factors such as the severity of injury, underlying comorbidities and the presence of biomarkers indicating renal repair mechanisms.
A 2022 Nephron review calls AKD the “missing link” between AKI and CKD, emphasizing the need for follow-up labs and patient education [8]. If kidney function hasn’t bounced back within that 90-day window CKD is usually diagnosed.
New research in the Yonsei Medical Journal shows how early post-discharge care—such as nephrology visits, medication reviews and blood pressure control—can slow progression to irreversible kidney damage [9]. Kidney disease progression after AKI increases the risk of developing chronic renal failure, chronic kidney failure, end stage kidney disease and end stage renal disease.
Meanwhile a 2024 American Journal of Physiology review looks into the biological mechanisms behind this progression. It points to inflammation, fibrosis (scarring) and microvascular injury as key drivers—and possible therapeutic targets—of the AKI-to-CKD transition [12]. Cardiovascular disease is also a major cause of morbidity and mortality in patients with a history of AKI.
Clinical Management Principles
When it comes to managing AKI a few core principles apply across both hospital and outpatient settings:
- Treat the cause: Whether it’s volume depletion, infection or obstruction the underlying trigger must be addressed first.
- Manage complications: Electrolyte imbalances like hyperkalemia, acidosis, pulmonary edema, metabolic acidosis or fluid overload may require urgent interventions.
- Adjust medications: Many common drugs (like ACE inhibitors, NSAIDs and contrast agents) should be stopped or adjusted during AKI.
- Monitor closely: Watch urine output, daily labs and fluid status.
- Escalate care when needed: Critically ill patients may need dialysis or continuous renal replacement therapy (CRRT) if they can’t maintain electrolyte balance or fluid status. Peritoneal dialysis is an option in certain situations, especially where resources are limited or in specific patient populations.
The Acute Dialysis Quality Initiative (ADQI) has developed consensus guidelines and classification systems for AKI management.
The sooner these are implemented the better the chances of preventing permanent kidney damage and the slide to CKD.
Closing Thoughts
Acute kidney injury is more than a short term health crisis—it’s a long term disease. As we learn more about AKI we have more opportunity to intervene early, personalize care and protect long term kidney health. By using advanced biomarkers, prevention focused strategies and recognizing AKD as a key phase clinicians can change the story for thousands of patients with kidney injury every year.
References
[1] Rahman, M., Shad, F., & Smith, M. C. (2012). Acute kidney injury: a guide to diagnosis and management. American family physician, 86(7), 631–639. https://pubmed.ncbi.nlm.nih.gov/23062091/
[2] Mercado, M. G., Smith, D. K., & Guard, E. L. (2019). Acute Kidney Injury: Diagnosis and Management. American family physician, 100(11), 687–694. https://pubmed.ncbi.nlm.nih.gov/31790176/
[3] Kellum, J. A., Romagnani, P., Ashuntantang, G., Ronco, C., Zarbock, A., & Anders, H. J. (2021). Acute kidney injury. Nature reviews. Disease primers, 7(1), 52. https://doi.org/10.1038/s41572-021-00284-z
[4] Jacob, J., Dannenhoffer, J., & Rutter, A. (2020). Acute Kidney Injury. Primary care, 47(4), 571–584. https://doi.org/10.1016/j.pop.2020.08.008
[5] Neyra, J. A., & Chawla, L. S. (2021). Acute Kidney Disease to Chronic Kidney Disease. Critical care clinics, 37(2), 453–474. https://doi.org/10.1016/j.ccc.2020.11.013
[6] Yoon, S. Y., Kim, J. S., Jeong, K. H., & Kim, S. K. (2022). Acute Kidney Injury: Biomarker-Guided Diagnosis and Management. Medicina (Kaunas, Lithuania), 58(3), 340. https://doi.org/10.3390/medicina58030340
[7] Gameiro, J., Fonseca, J. A., Outerelo, C., & Lopes, J. A. (2020). Acute Kidney Injury: From Diagnosis to Prevention and Treatment Strategies. Journal of clinical medicine, 9(6), 1704. https://doi.org/10.3390/jcm9061704
[8] Levey A. S. (2022). Defining AKD: The Spectrum of AKI, AKD, and CKD. Nephron, 146(3), 302–305. https://doi.org/10.1159/000516647
[9] Koh, E. S., & Chung, S. (2024). Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease Transition. Yonsei medical journal, 65(5), 247–256. https://doi.org/10.3349/ymj.2023.0306
[10] Bell, M., M Öberg, C., & Ewert Broman, M. (2025). Akut njurskada – prevention och behandling [Acute kidney injury - prevention and treatment]. Lakartidningen, 122, 23182. https://pubmed.ncbi.nlm.nih.gov/40421748/
[11] Moore, P. K., Hsu, R. K., & Liu, K. D. (2018). Management of Acute Kidney Injury: Core Curriculum 2018. American journal of kidney diseases : the official journal of the National Kidney Foundation, 72(1), 136–148. https://doi.org/10.1053/j.ajkd.2017.11.021
[12] Zhang, T., Widdop, R. E., & Ricardo, S. D. (2024). Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers. American journal of physiology. Renal physiology, 327(5), F788–F805. https://doi.org/10.1152/ajprenal.00184.2024
MORE DOCTORS & SCIENTISTS
